4D Molecular Therapeutics, Inc (FDMT)
followers
·
Follow
1 like
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| CEO: | David H. Kirn |
| Employees: | 120 |
| Web site: | 4dmoleculartherapeutics.com |
|
5858 HORTON STREET #455, EMERYVILLE, CA, 94608
5105052680
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa, choroideremia, and 4 D-310.
Please log in first to see chart